Company Overview and News

 
Neometals Offers 4 Great Opportunities For The Price Of 1

2018-04-09 seekingalpha
This article was first published on Trend Investing on March 9, 2018: therefore all data is as of that date.

1
Lithium Junior Miner News For The Month Of March 2018

2018-03-28 seekingalpha
Lithium spot and contract price news - Lithium spot prices moved sideways, whilst 2018 global LCE contract prices are up about 20%.

1
Lithium Miners News For The Month Of March 2018

2018-03-26 seekingalpha
Lithium spot and contract price news - Lithium spot prices were stable, while 2018 LCE global contract prices are about 20% higher than 2017.

 
Kidman Resources receives substantial valuation lift from Foster Stockbroking

2018-03-23 proactiveinvestors.com.au
Kidman Resources Limited (ASX:KDR) has caught the attention of Foster Stockbroking following an upgrade of the size of its Earl Grey JORC resource.

 
Neometals to acquire Mt Edwards Lithium Project

2018-03-15 proactiveinvestors.com.au
Neometals Ltd (ASX:NMT) is acquiring the Mt Edwards Lithium Project near Kalgoorlie in Western Australia for a cash consideration of $2.5 million and additional contingent payments.

3
2 Early Lithium Companies With Management To Succeed

2018-02-23 seekingalpha
The recent scare of lithium oversupply has driven down the entire lithium sector. This little understood deal between SQM and CORFO put investors into a panic, and many sold their holdings in fear. On the heels of this sector selloff, the US market entered a correction, which has driven the stock prices of lithium miners even lower.

1
AIS Resources Is Racing Towards Lithium Production In Northern Argentina

2018-02-07 seekingalpha
Canadian junior lithium explorer and developer optioned to buy into several promising lithium salars in Argentina.

 
Lithium Miners News For The Month Of January 2018

2018-01-28 seekingalpha
Lithium company news - SQM/Corfo settle their dispute over Salar de Atacama with SQM agreeing to pay royalties in return for a higher production quota.

 
Lithium Miners News For The Month Of January 2017

2018-01-28 seekingalpha
Lithium company news - SQM/Corfo settle their dispute over Salar de Atacama with SQM agreeing to pay royalties in return for a higher production quota.

 
Markets Live: ASX climbs but QBE drops

2018-01-23 theage.com.au
Shares are higher, taking a lead from more gains on Wall Street, although QBE is bucking the upward trend with a 5.2 per cent drop.

 
Markets Live: ASX climbs but QBE drops

2018-01-23 smh.com.au
Shares are higher, taking a lead from more gains on Wall Street, although QBE is bucking the upward trend with a 5.2 per cent drop.

 
3 Brine Lithium Developers Picked Following A Relative Value Analysis

2018-01-12 seekingalpha
“A great company is not a great investment if you pay too much for the stock.” - Benjamin Graham

1
Miners in the fast lane on electric vehicle surge

2018-01-03 theage.com.au
In car factories and showrooms, and on highways and streets around the world, a quiet revolution is gathering speed.

1
Miners in the fast lane on electric vehicle surge

2018-01-03 smh.com.au
In car factories and showrooms, and on highways and streets around the world, a quiet revolution is gathering speed.

 
Lithium Junior Miner News For The Month Of December 2017

2017-12-28 seekingalpha
Lithium market news - Roskill has tripled their lithium demand forecast from last year, from 328ktpa to ~1mtpa by 2026.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...